Literature DB >> 31769167

Assisted reproduction and justice: Threats to a new model in a low- and middle-income country.

David R Hall, Gerhard Hanekom.   

Abstract

Infertility is an unpredictable but widespread condition. While high-income countries grapple with when, or how to cover the costs of assisted reproductive technology (ART), such as in-vitro fertilisation (IVF), these services are generally only available to wealthy persons at private facilities in low- and middle-income countries (LMICs). Although the principle of non-interference with normal individual reproductive rights is robust, whether it is also the responsibility of collective society to provide the means (when ART applies) to achieve pregnancy, is controversial. Recently, a low-cost model was developed at a South African public institution. The target population for this model was "helpless and marginalised, childless couples", but a new threat has arisen, namely, infertile couples who could conceivably afford private care. In the allocation of this scarce resource, we argue for a prioritarian response that first addresses the worst-off, in order to even out unequal access imposed by sharp differences in income.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  LMIC; allocation; assisted reproduction; justice; reproductive rights

Year:  2019        PMID: 31769167     DOI: 10.1111/dewb.12252

Source DB:  PubMed          Journal:  Dev World Bioeth        ISSN: 1471-8731            Impact factor:   2.294


  2 in total

1.  Worldwide trend analysis of primary and secondary infertility rates over past decades: A cross-sectional study.

Authors:  Nasrin Borumandnia; Hamid Alavi Majd; Naghmeh Khadembashi; Hojat Alaii
Journal:  Int J Reprod Biomed       Date:  2022-02-18

2.  Economic costs of infertility care for patients in low-income and middle-income countries: a systematic review protocol.

Authors:  Purity Njagi; Wim Groot; Jelena Arsenijevic; Silke Dyer; Gitau Mburu; James Kiarie
Journal:  BMJ Open       Date:  2020-11-10       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.